Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Vioxx Withdrawal, First Thing For Merck Is Paying The Lawyers

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck increases reserve for legal defense costs related to Vioxx by $604 mil., bringing the total to $675 mil.; the company has not yet established a reserve to cover potential liability. A hearing to consolidate pretrial motions to a single federal judge is scheduled for Jan. 27.

You may also be interested in...



Bextra Withdrawal Costs Pfizer $1.28 Bil. In First Quarter

Pfizer will have to take charges to write off assets relating to the withdrawal of the COX-2 inhibitor in addition to $71 mil. in expected product returns. Pfizer has revised its April 5 guidance downward to reflect the withdrawal.

Bextra Withdrawal Costs Pfizer $1.28 Bil. In First Quarter

Pfizer will have to take charges to write off assets relating to the withdrawal of the COX-2 inhibitor in addition to $71 mil. in expected product returns. Pfizer has revised its April 5 guidance downward to reflect the withdrawal.

Merck Cost-Cutting Program Will Help Beat First Quarter Expectations, Company Says

Merck expects first quarter performance will come in at 62¢ per share, about 11% ahead of analysts' expectations. Despite stronger-than-expected first quarter, Merck is reaffirming full-year guidance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel